Sep 14, 2021 / 05:15PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Great. Well, good afternoon, everybody, and thanks for joining us for the next session. I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley. Very pleased to have Eli Lilly with us for the next session.
Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
So pleased to have Mike Mason with us from Lilly, who runs Diabetes. And we've got a wide range of topics to talk about. So looking forward to it.
Questions and Answers:
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive DirectorMike, I thought we could start with tirzepatide. Obviously, people are focused on the filing there and sort of next steps. So maybe you could just remind us where you are in terms of the filing and how that's progressing?
Trustpilot
